Shots:

• The companies collaborated to evaluate IO’s IO102-IO103 + MSD’s Keytruda vs Keytruda alone in the P-III trial for patients with previously untreated unresectable or MM. Biomarker studies will also be conducted while IO will sponsor the trial & MSD will provide Keytruda
• The P-I/II trial of combination therapy in 30 patients with the same indication demonstrated ORR (73%) & CR rate (47%). The therapy can induce tumor regression & establish durable antitumor response while achieving a manageable tolerability profile
• IO102 & IO103 are the immune-modulatory vaccines targeting IDO & PD-L1. The therapy has received BTD from FDA for MM based on the P-I/II trial

  | Ref: PR Newswire | Image: IO Biotech